Drug Trial Radar · NCT03839524
A Trial Evaluating TG4050 in Ovarian Carcinoma.
Last checked: Nov 19, 2026Latest source record: Nov 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Dec 9, 2019
Primary completion
Oct 8, 2024
Study completion Oct 8, 2024
Sponsor
- Lead sponsor
- TransgeneIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Conditions
- Ovarian Carcinoma
- Fallopian Tube Cancer
- Peritoneal Carcinoma
Interventions
TG4050Drug
Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability (Adverse Event Reported Per CTCAE v5)Time frame: Up to 1 year . Adverse events were collected from treatment initiation weekly for the first six weeks, every three weeks thereafter until 30 days after the last treatment administration.
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Phoenix
Phoenix, Arizona
Mayo Clinic Jacksonville
Jacksonville, Florida
Mayo Clinic Rochester
Rochester, Minnesota
Institut Curie
Paris, France
Hôpital Pitié-Salpêtrière
Paris, France
IUCT Toulouse
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.